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Abstract
Introduction: Neovascular age-related macular degeneration (AMD) is the leading cause of severe, irreversible visual impairment in
people over 60 years of age. Neovascular AMD is characterized by abnormal growth of blood vessels under the retina, specifically the
macula. These vessels leak blood and fluids, damaging the retina and its photoreceptors, resulting in permanent loss of central vision.
Vascular endothelial growth factor-A (VEGF-A) has been shown to play a critical role in the pathogenesis of neovascular AMD. In the US,
ranibizumab, a VEGF-A blocker, is approved and indicated for the treatment of patients with neovascular AMD.
Aims: To review the clinical evidence for ranibizumab in the treatment of neovascular AMD.
Evidence review: Phase III clinical trial data have established ranibizumab as a safe and well-tolerated treatment for neovascular AMD.
Monthly intravitreal injections of ranibizumab result in a statistically significantly greater proportion of patients losing <15 letters of visual
acuity (VA) and statistically significant increases in the mean number of letters gained compared with controls. Anatomically, ranibizumab
results in stabilization in the mean area of choroidal neovascularization (CNV) and statistically significant reductions in the mean area of
leakage compared with controls. Although there is limited economic evidence available, ranibizumab therapy for neovascular AMD
appears to deliver a significant degree of value gain in terms of quality of life when compared with other neovascular AMD interventions.
Place in therapy: Clinical evidence establishes ranibizumab as a first-line therapy option for virtually all treatable neovascular AMD
patients. Updating neovascular AMD treatment guidelines to reflect the evidence base for ranibizumab as a preferred first-line therapy
would be beneficial for physicians in making informed treatment choices and ultimately helping to ensure the best care for patients.
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Core evidence place in therapy summary for ranibizumab in neovascular AMD
Outcome measure Evidence Implications
Patient-oriented evidence
Maintenance of visual acuity Clear 95% of patients maintain visual acuity; 34–40% of patients treated with ranibizumab experience a
clinically significant improvement of visual acuity (gaining 15 or more letters at 12 months)
Improvement in vision Clear Significantly more ranibizumab-treated patients have 20/40 (Snellen equivalent) vision after 12 and 24
months of treatment than sham-treated patients; significantly fewer ranibizumab-treated patients have
20/200 vision after 12 and 24 months of treatment than sham-treated patients
Quality of life Limited Patients treated with ranibizumab demonstrate improvements in vision-specific quality of life
assessments using the National Eye Institute Visual Function Questionnaire-25
Safety and tolerability Clear Serious adverse events (<0.1%) related to intravitreal injections, including those with ranibizumab, have
been associated with endophthalmitis and retinal detachments. Other serious ocular adverse events in
<2% of patients include intraocular inflammation and increased intraocular pressure
Disease-oriented evidence
Decrease in classic CNV Clear Ranibizumab treatment is associated with arrested growth of CNV
Decrease in leakage from CNV and
staining of RPE
Clear Ranibizumab treatment is associated with reduced leakage from CNV
Need for repeated PDT therapy Moderate Use of ranibizumab reduces the need for repeated PDT in the study eye when intravitreal ranibizumab
treatment is combined with verteporfin PDT
Decrease in OCT central retina
thickness
Moderate Mean and median central retina thickness, as measured by OCT, decreases beginning one day after the
first ranibizumab injection and over the next 3 months
continued overleaf...Scope, aims, and objectives
Ranibizumab (Lucentisﾮ; Genentech, Inc.) is a humanized
antigen-binding fragment (Fab) derived from a mouse monoclonal
antivascular endothelial growth factor-A (VEGF-A) antibody
(Rosenfeld et al. 2006a). Ranibizumab is indicated in the US for
the treatment of patients with neovascular age-related macular
degeneration (AMD) (Anon. 2007a).
This review summarizes the pathophysiology and natural history
of neovascular AMD, describes the options currently available for
the treatment of neovascular AMD, and examines the available
evidence for ranibizumab in this indication. A detailed analysis of
the large clinical evidence base for ranibizumab efficacy and
safety in the treatment of neovascular AMD is discussed,
including efficacy measures such as visual acuity (VA) and
anatomic outcomes, as well as safety and tolerability data for
ranibizumab in neovascular AMD patients. The appropriate place
for ranibizumab in the treatment armamentarium for neovascular
AMD is also discussed.
Methods
The English language medical literature in the following databases
was searched between April 24 and July 10, 2007:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966
to date
• Clinical Trials.gov, http//clinicaltrials.gov
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluations Database
(NHSEED), Health Technology Assessment (HTA),
http://www.crd.york.ac.uk/crdweb/
• NHS HTA, http://www.ncchta.org
• National Guideline Clearinghouse, http://www.guideline.gov
• Cochrane Database of Systematic Reviews (CDSR),
http://cochrane.org/index.htm. Entire site searched
• American Academy of Ophthalmology,
http://www.aao.org/aao/
The search terms used were “ranibizumab OR Lucentis AND
macular degeneration” and the cut-offs were from the beginning
of the database to the date of the search. For the definition of
levels of evidence, see Editorial Information on the inside back
cover of journal. Papers from sources that were not peer reviewed
or in which the search terms used were not the primary subject of
the paper were excluded.
The proceedings of the following society meetings were searched
for relevant abstracts using the terms “ranibizumab OR Lucentis
AND macular degeneration”:
• The Association for Research in Vision and Ophthalmology
(ARVO) 2004–2007
• American Academy of Ophthalmology (AAO) 2004–2006
• The Retina Society 2004–2005
• Combined Meeting of Club Jules Gonin and the Retina Society
2006
• American Society of Retina Specialists 2006
Table 1 summarizes the level of evidence for the ranibizumab
references located through literature searches.
Disease overview
Epidemiology and risk factors
AMD is a leading cause of severe, irreversible vision impairment
in developed countries (AAO 2006). The prevalence of AMD
increases with age; one in three people will be affected to some
degree by the age of 75 (Stone 2006). The overall prevalence of
neovascular AMD in the US population 40 years and older is
estimated to be 1.47%, with 1.75 million citizens having AMD
(Friedman et al. 2004; AAO 2006). Based on the increasing
number of older people in the population, it is estimated that the
number of people with AMD may increase by 50% to 2.95 million
by 2020 (Friedman et al. 2004).
There are multiple risk factors associated with AMD (Nowak
2006). Although age and family history are key risk factors, the
most consistent factor associated with the development of AMD
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...table continued
Outcome measure Evidence Implications
Disease-oriented evidence
Reduction in the amount of
macular fluid
Moderate Intravitreal injections of ranibizumab rapidly reduce the amount of macular fluid; injections are stopped
if the macula is fluid-free, and when resumed, a single injection is usually sufficient to restore a
fluid-free macula
Economic evidence
Value gain associated with
ranibizumab
Limited Ranibizumab for the treatment of neovascular AMD improves the average long-term vision with a value
gain of greater than 15%
AMD, age-related macular degeneration; CNV, choroidal neovascularization; OCT, optical coherence tomography; PDT, photodynamic therapy; RPE, retinal pigment epithelium.275
is smoking (Klein et al. 2004). This modifiable risk factor doubles
the risk of AMD, with an apparent dose–response relationship
that increases with a greater number of pack years smoked
(AAO 2006).
Several studies suggest that hypertension and cataract surgery
also increase the risk of progression to late AMD, but the link is
not conclusive (Klein et al. 2004). For other potential risk factors
such as inflammatory disease, obesity, serum lipids,
atherosclerotic vascular disease, and hyperopia, the findings are
less consistent and the associations are often weaker (Klein et al.
2004). Diabetes has been hypothesized to increase the risk of
AMD, but few epidemiologic studies have found such a risk (Klein
et al. 2004). Similarly, exposure to ultraviolet (UV) light has been
postulated as a cause of AMD, but no studies have demonstrated
increased risk associated with UV-B exposure (Klein et al. 2004).
Family history is an important risk factor for AMD, and some
individuals may have a genetic predisposition for developing
AMD. In 2005, four articles described the increased risk of AMD
associated with polymorphisms of complement factor H
(HF1/CFH) (discussed in Moshfeghi & Blumenkranz 2007). One
variant in particular, Y402H, may account for approximately 50%
of AMD cases (Hageman et al. 2005; Kuehn 2005). Recently, three
additional genes that also potentially confer risk for AMD—
LOC387715 (ARMS2), PLEKHA1, and HTRA1—have been
identified. There have been conflicting reports on the role of these
three genes in AMD pathophysiology but there is evidence that
suggests that the single nucleotide polymorphism (SNP)
rs10490924 in the LOC387715 (ARMS2) gene and the
rs11200638 SNP in HTRA1 contribute to the risk of development
of AMD (reviewed in Ross et al. 2007). A more recent study
suggests that the SNP in the LOC387715 (ARMS2) gene has
direct effects on AMD risk presumably by affecting protein
function, whereas the SNP in HTRA1 may be through an indirect
pathway (Kanda et al. 2007). Analysis of the population-
attributable risk of AMD estimates that HF1, LOC387715
(ARMS2), and cigarette smoking together explain 61% of the risk
for AMD (Schmidt et al. 2006).
Several other genes have had at least one positive correlation
with risk for AMD. Multiple variations in complement factor B (BF)
and component 2 (C2) genes are associated with either increased
risk for AMD or providing protective effects against AMD,
depending on the variant gene present (Gold et al. 2006); the
R32Q single nucleotide polymorphism of BF (H7) and a variant in
intron 10 of C2 confer a significantly reduced risk of AMD (Gold et
al. 2007). Recently, a role for complement C3 in the pathogenesis
of AMD has also been described (Yates et al. 2007). It is likely that
several different combinations of gene variants contribute to the
risk for development of AMD. Continuing research will expand our
knowledge of the genetics of AMD.
Disease pathophysiology of neovascular AMD
There are two clinical forms of AMD: dry AMD and neovascular
AMD (Haddad et al. 2006). Dry AMD accounts for approximately
85% of total AMD cases (Haddad et al. 2006) and is characterized
by off-white to yellow subretinal deposits called drusen and/or
retinal pigment epithelium (RPE) irregularities. Some patients with
dry AMD may have functional limitations including fluctuating
vision, impaired reading, and limited vision at night or under
conditions of reduced illumination, although they generally have
good central vision (20/40 or better) (Fine et al. 2000). Dry AMD
can progress to geographic atrophy and/or neovascular AMD.
Geographic atrophy, sometimes described as the end stage of
dry AMD, is characterized by localized areas of RPE and neural
retina degeneration without subretinal neovascularization.
Neovascular AMD, also known as “wet AMD” or “exudative
AMD,” makes up about 15% of total AMD cases (Haddad et al.
2006) and is characterized by choroidal neovascularization (CNV),
usually involving the fovea (Nowak 2006). Development of
neovascular AMD is usually accompanied by changes in VA that
progress over weeks to months or longer (Brown et al. 2000).
Visual changes can manifest as blurring, distortion, or the
presence of dark spots in the central visual field (scotoma). The
onset of neovascular AMD is heralded by the appearance of
subretinal hemorrhage, intraretinal fluid, exudates, and lipid
and/or subretinal fluid in the macula occurring secondary to CNV,
resulting in loss of central vision (Brown et al. 2005). Untreated
neovascular AMD generally causes more profound visual loss
than dry AMD.
Many factors contribute to the disease process of neovascular
AMD: smoking, genetics, RPE dysfunction, drusogenesis, local
inflammation, and neovascularization (Nowak 2006). A complex
interaction between these factors leads to the development and
progression of neovascular AMD and vision loss (Fig. 1).
Smoking
Smoking contributes to the development and progression of AMD
in a number of ways. Firstly, smoking reduces the concentration
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Category Number of records
Full papers Abstracts
Initial search 44 146
records excluded 14 106
records included 30 40
Additional studies identified 00
Preclinical evidence 20
Level 1 clinical evidence
(systematic review, meta analysis)
40
Level 2 clinical evidence (RCT) 48
Level ≥3 clinical evidence 00
trials other than RCT 17 30
Expert panels on AMD 10
Economic evidence 22
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
AMD, age-related macular degeneration; RCT, randomized controlled trial.
Table 1 | Evidence base included in the reviewof macular pigment by as much as 50% in a dose–response
relationship (Hammond et al. 1996). Macular pigments protect
the macula by screening potentially harmful short-wavelength
light and serving as an antioxidant; thus, any reduction in this
pigment increases the risk for AMD (Hammond et al. 1996).
Second, nicotine and cotinine in the plasma of smokers
activates retinal phospholipase A2, causing the formation of
arachidonic acid (Sastry & Hemontolor 1998), a precursor to the
inflammatory mediators prostaglandins and leukotrienes, which
may contribute to macular degeneration (Sastry & Hemontolor
1998). Third, smoking is associated with the local activation of
macrophages that lead to an increase in photochemically
damaged lipids and proteins along with apoptosis of RPE cells
and photoreceptors (de Jong 2006). Thus, many molecular
interactions associated with smoking can contribute to the
development of AMD.
Genetics
Genetic factors contribute to the development and progression of
neovascular AMD via inflammation (Moshfeghi & Blumenkranz
2007), drusogenesis (DeWan et al. 2006; Moshfeghi &
Blumenkranz 2007), and neovascularization (DeWan et al. 2006).
Specifically, some SNPs in CFH, which is a major inhibitor of the
alternative complement pathway (Moshfeghi & Blumenkranz
2007), are likely to render the protein products of this gene
ineffective (de Jong 2006). The absence or low activity of CFH
leads to unchecked alternative pathway activation that, over time,
serves as an inflammatory stimulus leading to a permissive
environment for drusen formation (Moshfeghi & Blumenkranz
2007). Genetic variants in BF and C2 that are also involved in
complement activation are associated with risk for development
of AMD (Gold et al. 2006). As discussed above, the variations in
the LOC387715 (ARMS2), PLEKHA1, and HTRA1 genes are also
likely to contribute either directly or indirectly to the risk of
developing AMD.
RPE dysfunction
Impairment of RPE cell function is an early and crucial event in the
development of AMD. A driving force of RPE dysfunction is an
age-dependent phagocytic and metabolic insufficiency of
postmitotic RPE cells. These RPE cell deficiencies lead to
progressive accumulation of lipofuscin granules composed of
mostly lipids and proteins (Nowak 2006). Lipofuscin accumulation
imposes an ever-increasing burden on RPE cell function.
Increased lipofuscin in the RPE can lead to apoptosis, resulting in
accumulation of debris on and within Bruch’s membrane, and
eventual loss of photoreceptor function. Accumulated lipofuscin
absorbs light which damages the RPE and attracts macrophages,
thereby evoking a local autoimmune response that leads to
chronic inflammation (de Jong 2006). Products of lipofuscin
photooxidation in RPE cells also serve as triggers for complement
activation, further contributing to the chronic localized
inflammation (Zhou et al. 2006).
Drusogenesis
Drusen are amorphous deposits that accumulate extracellularly
in the area between the RPE and the inner collagenous zone of
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subretinal, intraretinal, or sub-RPE space
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Unregulated complement activation
Lipofuscinogenesis
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Leakage from fragile new vessels
Loss of photoreceptor function
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?
Fig. 1 | Factors and physiologic processes involved in the development and progression of neovascular AMD.
AMD, age-related macular degeneration; PED, pigment epithelium derived; RPE, retinal pigment epithelium.277
Bruch’s membrane (Nowak 2006). Some drusen-associated
constituents are locally produced by the RPE, choroid, and retina
(Mullins et al. 2000). A possible association between the buildup
of lipofuscin in RPE cells and drusen formation may exist, but
such a relationship has not been firmly established (Zhou et al.
2006). Drusen and age-related changes that occur in the vicinity
of Bruch’s membrane may lead to dysfunction and/or
degeneration of the RPE and retina by inducing ischemia and/or
restricting the exchange of nutrients and waste products
between the neural retina and choroid. Drusen themselves may
have a detrimental effect on vision, particularly with respect to
contrast sensitivity (Mullins et al. 2000). The presence of
inflammatory constituents within drusen, such as complement
activators, activation-specific complement fragments, and
membrane attack complex, may contribute to local inflammation
(Mullins et al. 2000; Russell et al. 2000; Anderson et al. 2002;
Donoso et al. 2006).
Local inflammation
Drusen form, at least in part, as a result of localized chronic
inflammation (Zhou et al. 2006; Moshfeghi & Blumenkranz
2007). Injured RPE cells activate and recruit choroidal dendritic
cells that may elicit an inflammatory or complement-mediated
response (Hageman et al. 2001). Regardless of the initiating
factor(s), local inflammation leads to up-regulation of
inflammatory cytokines and infiltration of macrophages,
resulting in localized damage and apoptosis of RPE cells,
photoreceptors, and other cells within the retina (de
Jong 2006).
Neovascularization
Angiogenesis, the formation and maturation of new blood
vessels via sprouting or splitting from existing vessels, is
characterized by a complex cascade of events (Kaiser 2006a).
In order to stimulate angiogenesis, the molecular machinery
must be unbalanced in favor of proangiogenic signaling (Nowak
2006). This results from an increase in proangiogenic factors
such as VEGF or a decrease in antiangiogenic factors such as
pigment epithelium-derived factor (PEDF).
VEGF-A is a primary driver of angiogenesis (Kaiser & Do 2007).
VEGF-A plays a critical role in the pathogenesis of neovascular
AMD through its effects on angiogenesis and vascular
permeability (Kaiser & Do 2007). Under normal conditions,
endothelial cells lining choroidal blood vessels of the retina are
resistant to angiogenic stimuli (Nowak 2006). However,
thickening of or damage to Bruch’s membrane, presence of soft
confluent drusen, RPE dysfunction, and pigment abnormalities
create a permissive environment for the initiation of
angiogenesis (AOA 2004). The resulting new vessels are fragile
and do not mature properly, leaking blood and/or fluid with
proteins and lipids into subretinal, intraretinal, or sub-RPE
spaces (AOA 2004). This neovascularization and leakage
results in the changes in vision associated with neovascular
AMD, including loss of VA, particularly when the fovea
is involved.
Natural history of AMD
The progression of AMD has been described and categorized by
the Age-Related Eye Disease Study Research Group (AREDS), as
presented in Table 2 (AREDS 1999, 2000, 2001). Patients with dry
AMD are categorized as having early AMD (category 2) or
intermediate AMD (category 3) while patients with neovascular
AMD are considered to have advanced AMD (category 4).
In early AMD, patients generally have central VA similar to patients
with a normal macula. There are little or no pigment epithelial
abnormalities, small to intermediate drusen, and a 1.3% risk of
progressing to advanced AMD within 5 years. Patients with
intermediate AMD have extensive medium-sized, intermediate
drusen, or one or more large drusen in one or both eyes. The
chances of progression to advanced AMD are increased in these
patients, with 18% progressing to advanced AMD at 5 years
(AREDS 2001). The odds for the development of advanced AMD
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AMD category
Category 1 No drusen or nonextensive small drusen only in both eyes
Category 2 Extensive small drusen, nonextensive intermediate
drusen, or pigment abnormalities in at least one eye
Category 3 Large drusen, extensive intermediate drusen, or
noncentral geographic atrophy in at least one eye
Category 4 Advanced AMD (defined by the presence of at least
one of the following: geographic atrophy, retinal
pigment epithelial detachment in one eye,
choroidal neovascularization, or scars of confluent
photocoagulation) or visual acuity less than
20/32 attributable to lesions of nonadvanced AMD,
such as large drusen in the fovea, in only one eye
Drusen size Based on largest drusen diameter as follows (relative to
the size of an average optic disc, considered by
convention to be 1500 ￿m)
Small drusen <63 ￿m (1/24 disc diameter, standard circle C-0)
Intermediate
drusen
≥63 ￿m but <125 ￿m
Large drusen ≥125 ￿m (1/12 disc diameter, standard circle C-1)
Drusen extent Variability in drusen size requires that total drusen area,
rather than drusen number, be considered
Small drusen Considered extensive if the cumulative area within two
disc diameters of the center of the macula equal to at
least that of the AREDS standard circle C-1 (with diameter
1/12 that of the average disc)—this corresponds to
approximately 15 small drusen from stereo photographs
or 5 to 10 small drusen by ophthalmoscopic examination.
Intermediate
drusen
Considered extensive if soft, indistinct drusen are
present and the total area occupied by the drusen is
equivalent to the area that would be occupied by
20 drusen each having a diameter of 100 ￿m. If no soft
indistinct drusen are present, intermediate drusen are
considered to be extensive when they occupy an area
equivalent to at least 1/5 of a disc area (approximately
65, 100-￿m diameter drusen)
AMD, age-related macular degeneration.
Table 2 | AMD categories and classifications [adapted from
Age-Related Eye Disease Study Research Group
(AREDS) 2000]at 5 years are 26% in patients in whom drusen are present
bilaterally, compared with 6.3% for patients with large drusen in
only one eye. Patients with advanced AMD (AREDS category 4)
have either neovascular AMD or geographic atrophy involving the
fovea; therefore, VA is usually already affected in this category
(AREDS 2001). Geographic atrophy is an advanced form of dry
AMD in which there are one or more zones of sharply defined RPE
and/or choriocapillaris atrophy. Geographic atrophy can lead to
progressive loss of central vision if the fovea is involved (AAO
2006). Patients with advanced AMD or vision loss due to
advanced dry AMD in one eye have a 43% chance of developing
CNV or geographic atrophy in the fellow eye within 5 years
(AREDS 2001).
In the Macular Photocoagulation Study, cases of classic and
occult CNV were classified based on fluorescein angiography (FA)
(MPS 1991; AAO 2006). Classic CNV is recognized as an area of
bright, well-demarcated hyperfluorescence in the early phase of
the angiogram, with progressive pooling of dye in the overlying
subsensory retinal space during the late phases of the angiogram.
Occult neovascularization consists of CNV that has indistinct or
poorly demarcated boundaries on FA. Such CNV may be
associated with an RPE detachment and/or late leakage of an
undetermined source. Using these definitions, lesions associated
with neovascular AMD are often categorized clinically and
angiographically as occult, classic, or mixed occult and classic
(minimally or predominantly classic) CNV (AAO 2006).
New approaches for understanding and treating
neovascular AMD
VEGF-A is a primary driver of angiogenesis and plays a critical
role in the pathogenesis of neovascular AMD through its effects
on angiogenesis and vascular permeability (Kaiser & Do 2007).
VEGF-A expression is increased in pigment epithelial cells during
the early stages of AMD (Kliffen et al. 1997), suggesting that
VEGF-A may play a role in the initiation of neovascularization
rather than being secondary to it (Kaiser 2006a). High
concentrations of VEGF-A have been observed in excised
choroidal neovascular membranes from AMD patients (Kvanta et
al. 1996), and increased retinal and vitreous VEGF-A levels are
found in both animals and humans with ischemic retinopathies
induced by oxidative damage or hypoxia (Aiello et al. 1994; Pe’er
et al. 1995). Thus, VEGF has become a frequent target for the
development of new treatments for ocular neovascular diseases
(Kaiser 2006a).
Two anti-VEGF therapies for AMD are FDA approved, with others
in various stages of development. Currently available anti-VEGF
agents include an aptamer (pegaptanib sodium), which targets
the VEGF165 isoform of VEGF-A, and the monoclonal antibody
fragment ranibizumab, which targets all VEGF-A isoforms and
cleavage products. Off-label bevacizumab is being used as a
treatment for neovascular AMD as well. Bevacizumab is a
monoclonal antibody specific for VEGF-A that is approved for the
treatment of metastatic colorectal cancer and non-small cell lung
cancer. Other anti-VEGF therapies in development include small
interfering RNA (siRNA)-based therapies that silence specific
genes via targeted degradation of mRNA, receptor tyrosine kinase
inhibitors that target downstream activation of VEGF receptors,
and VEGF Trap, which is a chimera of the ectodomains of VEGF
receptor 1 and VEGF receptor 2 fused to an Fc portion of an
antibody. VEGF Trap binds to VEGF-B and placental growth factor
(PlGF) in addition to VEGF-A. The variable efficacy of these
agents might reflect the specifics of how they target and block
angiogenesis. In particular, whether or not an agent binds one or
all VEGF-A isoforms appears to have a substantial impact on
efficacy. Although the efficacy of these other antiangiogenic
approaches has yet to be fully examined, further advances in
treatment are likely (Kaiser 2006a). Additional targets are being
explored for potential treatment of AMD, in particular the
complement component proteins that have recently been
identified as strong risk factors for the disease.
Current therapy options
The American Academy of Ophthalmology notes that even
patients with neovascular AMD who receive appropriate
treatment generally have a poor visual prognosis (AAO 2006). The
treatment recommendation and follow-up plans for the treatment
of AMD recently underwent limited revision by the American
Academy of Ophthalmology Retina Panel (AAO 2006). The
recommendations were given an explicit rating based on the
importance to the care process and the strength of the evidence
that supports the recommendation (AAO 2006).
The risks, benefits, and complications of the treatment should be
discussed with the patient and informed consent obtained.
Treatment options depend on the stage of the disease and
diagnoses, as discussed below. Physicians are encouraged to
promote healthy eating and to educate patients about the
symptoms of AMD, thus prompting earlier presentation to
ophthalmologists (Morris et al. 2007). Because of the
considerable health benefits of smoking cessation, all patients
who are currently smoking should be advised to stop regardless
of AMD status (AAO 2006). Current smokers who modify their
behavior may be able to reduce their risk of developing AMD
(Tomany et al. 2004).
Observation is recommended, with no medical or surgical
therapies, for patients with no clinical signs of AMD (AREDS
category 1), early AMD (AREDS category 2), or advanced AMD
with bilateral subfoveal geographic atrophy or disciform scars
(AAO 2006). Since few patients in category 1 or 2 progress to
advanced AMD, the effects of treatments within these patient
populations cannot be evaluated (AREDS 2001). Recommended
follow-up for these patients includes a return exam at
6–24 months or a prompt exam for new symptoms suggestive of
CNV with no fundus photos or fluorescein angiography (FA)
unless the patient is symptomatic (AAO 2006).
The AAO Retina Panel recommends antioxidant vitamin and
mineral supplements for patients with intermediate AMD (AREDS
category 3) or advanced AMD in one eye (AREDS category 4)
(AAO 2006). Recommended follow-up for these patients includes
the monitoring of monocular near vision via reading or Amsler
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grid, a return exam at 6–24 months if the patient is asymptomatic,
with a prompt exam for new symptoms suggestive of CNV, fundus
photography as appropriate, and FA if there is evidence of edema
or other signs and symptoms of CNV.
For patients with CNV, a range of treatment options exists,
depending on lesion type. The current treatment guidelines
indicate that patients with subfoveal CNV can be treated with
photodynamic therapy (PDT) with verteporfin, pegaptanib
sodium, or ranibizumab (AAO 2006). Patients should be treated
within 1 week after FA (AAO 2006). In order to describe the
therapeutic value of ranibizumab for the treatment of neovascular
AMD, the efficacy of other treatments currently used—PDT with
verteporfin, pegaptanib sodium, and off-label bevacizumab—is
presented for comparison.
Ranibizumab
Ranibizumab intravitreal injection 0.5 mg is recommended for
patients with subfoveal CNV. For this treatment, the AAO Retina
Panel puts no limitations on treatment by the size or type of
lesion. Recommended follow-up includes instructions to patients
to report any symptoms of endophthalmitis without delay.
Patients treated with ranibizumab should have follow-up exams,
with re-treatments every 4 weeks as indicated, and undergo
monitoring of monocular near vision (AAO 2006). The evidence for
the use of ranibizumab is evaluated in the Clinical evidence
section, below.
PDT with verteporfin
The AAO Retina Panel endorses the use of PDT with verteporfin
as recommended in the Treatment of Age-Related Macular
Degeneration with Photodynamic Therapy (TAP) and Verteporfin
in Photodynamic Therapy (VIP) reports (TAP 1999; Bressler 2001;
VIP 2001; Barbazetto et al. 2003) if the patient has new or
recurrent CNV where the classic component is >50% of the lesion
and the entire lesion is ≤5400 ﾵm in greatest linear diameter (AAO
2006). Off-label use of PDT with verteporfin can be considered in
patients with minimally classic CNV or occult with no classic CNV
if vision is <20/50 or if CNV is <4 Macular Photocoagulation Study
(MPS) disc areas in size when vision is >20/50 and there is
evidence of recent disease progression, defined as a recent
decrease in vision, an increase in size of the lesion, or hemorrhage
associated with the lesion during the previous 3 months (AAO
2006). Follow-up recommendations include return exams
approximately every 3 months until the patient is stable, with re-
treatments as necessary, FA or other imaging as indicated, and
monitoring of monocular near vision (AAO 2006).
Two multicenter, double-masked, placebo-controlled,
randomized clinical trials with 2 years of results supported
approval of PDT with verteporfin as a treatment for neovascular
AMD (Bressler 2001). In these trials, the primary outcome was the
proportion of eyes with <15 letters of VA loss at 12 and 24 months
(TAP 1999; Bressler 2001). Patients received either verteporfin
(6 mg/m2 body surface area) or placebo (5% dextrose in water)
followed by laser light, with the same treatment administered
every 3 months for up to 24 months if FA showed evidence of
fluorescein leakage (TAP 1999; Bressler 2001). At 12 months,
61% of verteporfin-treated patients and 46% of placebo-treated
patients lost <15 letters of VA compared with baseline (P<0.001).
At this time point, subgroup analyses indicated that the VA benefit
was clearly demonstrated in predominantly classic CNV lesions,
especially when there was no occult CNV present (TAP 1999). At
24 months, 53% of verteporfin-treated patients lost <15 letters,
compared with 38% of placebo-treated patients (P<0.001).
Subgroup analyses at 24 months indicated that patients with
predominantly classic CNV lesions were more likely to exhibit a
treatment benefit (Bressler 2001). Secondary treatment
outcomes, including the proportion of eyes that had lost
<30 letters compared with baseline, mean changes in VA, mean
changes in contrast threshold, and the angiographic outcomes of
the progression of CNV and the size of the lesion all favored PDT
over placebo at the 12-month and 24-month intervals (TAP 1999;
Bressler 2001). A recent report of the 5-year results from these
trials has shown that vision outcomes remain relatively stable
between month 24 and month 60, even though the treatment rate
is low during this period (Kaiser 2006b).
Pegaptanib sodium
Pegaptanib sodium 0.3 mg intravitreal injections can be used in
patients with new or recurrent subfoveal CNV with predominantly
classic lesions ≤12 MPS disc areas in size. The AAO Retina Panel
recommends that this treatment can be used in patients with
minimally classic or occult CNV with no classic lesions where the
entire lesion is ≤12 disc areas in size, subretinal hemorrhage
associated with CNV comprises ≤50% of the lesion, there is lipid
present, and/or the patient has lost 15 or more letters of VA during
the previous 12 weeks (AAO 2006). Recommended follow-up
includes instructions to patients to report without delay any
symptoms suggestive of endophthalmitis, including eye pain or
increased discomfort, worsening eye redness, blurred or
decreased vision, increased sensitivity to light, or an increased
number of floaters. In addition, the patient should return for
exams and re-treatment every 6 weeks as indicated.
Two pivotal clinical trials of pegaptanib sodium demonstrated the
efficacy and safety of this pegylated aptamer in the treatment of
neovascular AMD (Gragoudas et al. 2004). The primary efficacy
outcome of the VEGF Inhibition Study in Ocular
Neovascularization (VISION) trials was the proportion of patients
who lost <15 letters of VA between baseline and week 54.
Patients received either intravitreal pegaptanib injections (0.3, 1.0,
or 3.0 mg) or sham injections every 6 weeks for 48 weeks. A
significantly greater proportion of patients treated with
pegaptanib than sham-treated patients lost <15 letters (P<0.001
for 0.3 mg vs sham; P<0.001 for 1.0 mg vs sham; and P=0.03 for
3.0 mg vs sham). A total of 33% of pegaptanib-treated patients
maintained or gained VA, compared with 23% of sham-treated
patients (P=0.003). A smaller percentage of patients in the
pegaptanib groups than in the sham-injection group had a Snellen
equivalent VA of 20/200 or worse in the study eye at week 54
(P<0.001 for the comparison between all treatment groups and
the sham-injection group). Angiographic examinations showed a
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and the severity of leakage in the groups receiving pegaptanib
compared with the sham-injection group. Pegaptanib treatment
appears to be safe; however, serious ocular adverse events (AEs)
such as endophthalmitis (1.3% of patients), traumatic lens injury
(0.7% of patients), and retinal detachment (0.6% of patients) have
been reported. These studies demonstrate that pegaptanib is a
safe and efficacious treatment for AMD, but its long-term safety
has not been established (Gragoudas et al. 2004).
Off-label bevacizumab
Bevacizumab is approved for the treatment of colorectal and non-
small cell lung cancer. Bevacizumab is being used off-label as a
treatment for neovascular AMD and other neovascular diseases
of the eye. The AAO Retina Panel notes that physicians should
provide appropriate education to the patient and obtain informed
consent with respect to the off-label status of the drug (AAO
2006). There is no limitation on the size of the lesion that can be
treated with off-label bevacizumab, and treatment should be
followed by return exams, with re-treatments every 4–8 weeks as
indicated, with monitoring of vision (AAO 2006).
To date, no large, controlled, randomized clinical trials have
been completed with off-label bevacizumab to demonstrate its
safety or efficacy; however, there have been a number of small
studies published. The results from one uncontrolled, open-label
trial of systemic off-label bevacizumab therapy for the treatment
of neovascular AMD have been reported (Michels et al. 2005).
Systemic off-label bevacizumab was infused at the same dose
and dosing interval currently approved for the treatment of
metastatic colorectal cancer: 5 mg/kg with three initial infusions
at 2-week intervals (Michels et al. 2005). In the study eye,
significant increases in VA were evident within 1 week of
treatment and continued through week 12. Median and mean
central retinal thickness measurements decreased over 12
weeks. Angiography revealed a marked reduction or an absence
of leakage from CNV. Similar results were seen in the fellow eye.
Seven of nine patients experienced mildly elevated blood
pressure (Michels et al. 2005). There are major disadvantages
associated with systemic off-label bevacizumab therapy, the
most significant of which is the possibility of life-threatening
systemic AEs. These include increased risk of potentially fatal
thromboembolic events and reduced wound healing after
surgery, and possible detrimental effects to the normal eye
(Michels et al. 2005).
Long-term studies of the efficacy and safety of systemic off-label
bevacizumab for the treatment of AMD have not been performed.
There are several case studies and case series using intravitreal
injection of off-label bevacizumab (Rosenfeld et al. 2005; Avery et
al. 2006; Bashshur et al. 2006; Spaide et al. 2006). Dosing and
follow-up varied. Improvements in VA from baseline (Avery et al.
2006; Bashshur et al. 2006; Spaide et al. 2006), decreased retinal
thickness by optical coherence tomography (OCT) (Avery et al.
2006; Bashshur et al. 2006; Spaide et al. 2006), and a reduction
in angiographic leakage in most patients (Rosenfeld et al. 2005;
Avery et al. 2006; Bashshur et al. 2006; Spaide et al. 2006) have
been reported. Intravitreal injections of off-label bevacizumab
were judged to be safe, with no significant ocular or systemic AEs
observed; however, none of these retrospective studies
systematically followed patients for safety issues (Rosenfeld et al.
2005; Avery et al. 2006; Bashshur et al. 2006; Spaide et al. 2006).
Only one study excluded patients with uncontrolled hypertension
or recent myocardial infarction or cerebral vascular accident
(Avery et al. 2006). Long-term studies of the efficacy and safety of
off-label bevacizumab intravitreal injection for the treatment of
AMD have not been performed, but are being planned. The
National Eye Institute’s Comparison of Age-Related Macular
Degeneration Treatments Trial (CATT) is being organized to
directly evaluate the efficacy and safety of ranibizumab versus
bevacizumab in the treatment of neovascular AMD. The results of
the trial will most likely be available in several years, by which time
new neovascular AMD therapies may have already changed the
treatment landscape.
Thermal laser photocoagulation surgery
Another option that may be considered for patients with new or
recurrent subfoveal CNV is thermal laser photocoagulation surgery,
although it is rarely used (AAO 2006). The AAO Retina Panel states
that it is useful for lesions that are <2 MPS disc areas and when VA
is 20/125 or worse, especially if PDT is contraindicated or not
available (AAO 2006). Follow-up includes a return exam with FA
approximately 2–4 weeks after treatment, and then at 4–6 weeks
and thereafter depending on clinical and angiographic findings. Re-
treatment should be given as indicated, with continued monitoring
of monocular near vision. For patients with new or recurrent
extrafoveal classic CNV or juxtafoveal classic CNV, the only
treatment option recommended by the AAO Retina Panel is thermal
laser photocoagulation surgery (AAO 2006). This therapy may be
considered for juxtapapillary CNV as well.
New drugs in development
The Pharmaceutical Research and Manufacturers of America
(PhRMA) database lists 25 new medicines for the indication “age-
related macular degeneration” at various stages of development.
These include anti-VEGF therapies, steroidal therapies, radiation
therapy, and endogenous antiangiogenic factors (Nowak 2006).
Many of the drugs in development are anti-VEGF therapies,
including the soluble receptor decoy VEGF Trap, 2 siRNA-based
therapies [Sirna-027, which targets VEGF receptor 1 mRNA, and
bevasirinib (Cand5), which targets VEGF-A mRNA], and several
tyrosine kinase inhibitors [oral vatalanib (PTK787), subtenons AG-
013958, topical TG100801, and topical pazopanib]. Two drugs in
development target genes involved in the production of VEGF rather
than the activity of VEGF. Sirolimus (rapamycin) impacts upon the
mammalian target of rapamycin (mTOR) and causes a decrease in
VEGF production and a reduction in the response of vascular
endothelial cells to stimulation by VEGF (Dejneka et al. 2004).
Steroidal therapies such as anecortave acetate and triamcinolone
acetonide have antiangiogenic activity in addition to their
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antiinflammatory properties and may therefore inhibit CNV. A
phase III trial for the treatment of CNV demonstrated that
anecortave acetate was non-inferior to PDT, with the benefit
outweighing the risk associated with the drug’s mode of
administration via posterior juxtascleral depot (PJD) (Slakter et
al. 2006). The 2-year results of a retrospective analysis of
triamcinolone acetonide added to PDT with verteporfin therapy
stabilized best-corrected visual acuity (BCVA) and there was a
reduction in the need for re-treatment (Ruiz-Moreno et al. 2007).
Another therapy in development is beta-radiation therapy, which
has a long history of use in ophthalmology (Kirwan et al. 2003).
A clinical trial (CABERNET) of focal beta brachytherapy with
strontium-90 delivered locally is expected to start patient
recruitment soon to evaluate the safety and efficacy of this
system in the treatment of subfoveal CNV associated with
neovascular AMD. Several endogenous antiangiogenic factors
such as angiostatin, endostatin, and PEDF are possible future
therapeutics (Nowak 2006).
Unmet needs in neovascular AMD
The ultimate unmet need in neovascular AMD is prevention of
the disease. To date, there is no treatment approved for
preventing the development of neovascular AMD (SanGiovanni
et al. 2007). However, incorporation of the AREDS vitamin and
mineral supplement into the diet of patients with dry AMD may
help to at least delay the onset of neovascular AMD (AREDS
2001). Recent advances in AMD genetics may provide the basis
for the development of diagnostic tests to determine an
individual’s risk for AMD. Advances in discovering specific
biomarkers for AMD may also provide a very early detection
method to direct intervention before development of
the disease.
Until the advent of anti-VEGF agents such as ranibizumab, there
was a tremendous unmet medical need for effective treatments
for neovascular AMD. The success of anti-VEGF agents for
neovascular AMD has changed the standard of care and raised
expectations for treatment beyond a slowing of vision loss; now,
patients and physicians expect stabilization or improvement in
vision. Notwithstanding the impressive efficacy of anti-VEGF
agents, there are still unmet needs in neovascular AMD
treatment. Even better efficacy is a clear unmet need, but more
important is better modes of treatment administration. Currently,
anti-VEGF agents are administered via intravitreal injection at
least once per month. The injection procedure, while
surprisingly well accepted by patients, is not an optimal method
of drug delivery. Some patients and physicians find the injection
frequency objectionable, and it may simply not be feasible in
particular circumstances. An injectable or implantable long-
acting delivery device for anti-VEGF agents would be a
significant step forward. Alternatively, the development of a
simple eye drop formulation would also be highly desirable.
These more convenient modes of administration could
potentially reduce the amount of time AMD patients need to
spend in physicians’ offices, reducing strain on practices
while making effective treatment less taxing to patients and
their caregivers.
Clinical evidence with ranibizumab in
neovascular AMD
Before exploring the body of clinical evidence for ranibizumab, it
is important to understand the rationale for the drug and the
design efforts that went into its creation. A rational drug design
process was utilized with the following desirable qualities for an
effective ocular antiangiogenic therapeutic: local deliverability into
the eye, ability to penetrate through the retina to the sub-RPE
space, high affinity for its target (all forms of VEGF-A), and safety
and tolerability with minimal systemic exposure. In order to
achieve these characteristics for a neovascular AMD treatment, a
humanized anti-VEGF-A Fab was created. Ranibizumab was
generated after several rounds of molecular modification that
significantly increased binding affinity for its target, VEGF-A.
Because of the location on VEGF-A to which ranibizumab binds,
it has the ability to bind all VEGF-A forms with high affinity and
inhibit their biologic activities (Genentech, Inc. unpublished data).
Preclinical evidence suggested that ranibizumab had potential to
be an effective treatment for neovascular AMD. In-vivo
pharmacokinetic studies in a monkey model indicated a favorable
intraocular half-life (terminal half-life of approximately 3.6 days
after intraocular administration of 0.5 mg ranibizumab) and
systemic half-life (terminal half-life of approximately 15.5 hours
after intravenous administration of 1 mg ranibizumab) (Gaudreault
et al. 2005). A primate laser-induced CNV model of neovascular
AMD was used to demonstrate that in pretreated eyes, intravitreal
ranibizumab prevented CNV. In addition, eyes with established
laser-induced CNV showed decreased leakage on FA and rapid
resolution of CNV after intravitreal injections of ranibizumab
(Krzystolik et al. 2002).
Six clinical studies investigating ranibizumab in the treatment of
neovascular AMD have been published to date (Fig. 2).
• FVF2128g: a phase I/II, 30-week, multicenter, controlled, open-
label study of intravitreally administered ranibizumab (0.3 mg or
0.5 mg) versus usual care (UC) in patients with subfoveal
predominantly or minimally classic AMD-related CNV (Heier et
al. 2006a; Fig. 2a). To maximize the safety information obtained
and provide an opportunity for those randomized to UC to later
receive ranibizumab, patients were permitted to cross over to
the alternative treatment after 3 months of randomized
treatment (Heier et al. 2006a).
• FOCUS: a phase I/II, 2-year, multicenter, randomized, single-
masked, controlled study of injection of ranibizumab 0.5 mg
(n=106) or sham (n=56) in combination with verteporfin PDT
versus verteporfin PDT alone (Heier et al. 2006b; Fig. 2b). This
study was undertaken to investigate the safety and efficacy of
intravitreal ranibizumab treatment combined with verteporfin
PDT in patients with predominantly classic CNV secondary to
AMD (Heier et al. 2006b).
• PrONTO: a phase II, 2-year, open-label, single-center,
uncontrolled, investigator-sponsored study to evaluate an OCT-
guided variable-dosing regimen with intravitreal ranibizumab for
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Fig. 2 | Study designs investigating ranibizumab in patients with neovascular AMD
Fig. 2a | Phase I/II, 30-week, multicenter, controlled, open-label study of intravitreally administered ranibizumab in patients with AMD
(Trial FVF2128g; Heier et al. 2006a). AMD, age-related macular degeneration; CNV, choroidal neovascularization
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Verteporfin
PDT
(n=162)
Predominantly
classic lesions
(n=162)
Monthly ranibizumab* injections 0.5 mg
with PDT as necessary
(n=106)
Monthly sham injections
with PDT as necessary
(n=58)
Neovascular AMD
with subfoveal CNV;
central retinal
thickness of at least
300 µm as
measured by OCT
(n=40)
Ranibizumab re-treatment performed if:
• A loss of 5 letters in conjunction with
  f l uid in the macula (detected by OCT)
• An increase in OCT central retinal
  thickness of at least 100 µm
• New onset class 1c CNV
• New macular hemorrhage
• Persistent macular fluid detected by
OCT at least 1 month after 
  previous injection
3 monthly ranibizumab
injections 0.5 mg
Fig. 2b | Phase I/II, 2-year, multicenter, randomized, single-masked, controlled study of 0.5 mg ranibizumab in patients with AMD
and PDT administered 7 days before (FOCUS trial; Heier et al. 2006b). *Lyophilized ranibizumab was used during the first
12 months of the trial. The formulation was replaced with the FDA-approved liquid formulation at varying time points during
the second year of the trial. The trial protocol was amended on March 19, 2004 increasing the interval between PDT and
subsequent ranibizumab/sham injection to a minimum of 28 days. AMD, age-related macular degeneration; PDT, verteporfin
photodynamic therapy
Fig. 2c | 2-year open-label, single-center, uncontrolled, investigator-sponsored clinical study of neovascular AMD patients with
subfoveal CNV (PrONTO Trial; Fung et al. 2007b). AMD, age-related macular degeneration; CNV, choroidal
neovascularization; OCT, optical coherence tomography283
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Fig. 2d | Multicenter, 2-year, double-blind, sham-controlled study of 24 intravitreal injections of ranibizumab or sham injections in
patients with choroidal neovascularization AMD (MARINA Trial; Rosenfeld et al. 2006). *PDT allowed if the CNV became
predominantly classic. Protocol amended to allow PDT for minimally classic or occult disease with no classic lesions that
were no larger than four optic disc areas and accompanied by a loss of ≥20 letters from baseline visual acuity. AMD, age-
related macular degeneration; CNV, choroidal neovascularization; PDT, verteporfin photodynamic therapy
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Fig. 2e | Phase III, multicenter, randomized, double-masked, active treatment controlled study of ranibizumab compared with PDT in
subjects with predominantly classic subfoveal age-related macular degeneration (ANCHOR Trial; Brown et al. 2006a). *The
necessity for repeat PDT treatment was determined based on angiographic evidence of vascular leakage. Thus, subjects
randomized to the PDT group had the potential to have a verteporfin PDT treatment every 3 months. Subjects randomized to a
ranibizumab group had the potential to receive a sham PDT treatment every 3 months. AMD, age-related macular
degeneration; CNV, choroidal neovascularization; PDT, verteporfin photodynamic therapy
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Fig. 2f | Phase IIIb, randomized, double-masked, sham-controlled study of ranibizumab compared with sham injections in a fixed
dosing regimen of three monthly doses followed by mandated quarterly dosing in subjects with primary or recurrent subfoveal
CNV with or without a classic CNV component (PIER Trial; Anon. 2007a). *PDT allowed at investigator discretion: if the CNV
became predominantly classic, or if loss of ≥20 letters on two consecutive visits and small (≤4 disc areas), minimally classic
or occult with no classic lesions, with presumed recent disease progression, are observed. CNV, choroidal neovascularization;
PDT, verteporfin photodynamic therapythe treatment of patients with neovascular AMD (Fung et al.
2007b; Fig. 2c). Patients with subfoveal CNV (n=40) and central
retinal thickness of at least 300 ﾵm as measured by OCT
received three consecutive monthly intravitreal injections of
ranibizumab 0.5 mg. Thereafter, re-treatment with ranibizumab
was performed based on specific re-treatment criteria (a loss of
at least 5 letters in conjunction with increased fluid in the
macula, increased central retinal thickness of at least 100 ﾵm,
new-onset classic CNV, new macular hemorrhage, or
persistent macular fluid following an injection of ranibizumab at
the prior study visit) (Fung et al. 2007b).
• MARINA: one of two pivotal phase III, multicenter, double-
blind 24-month studies, which compared monthly intravitreal
injections of ranibizumab 0.3 or 0.5 mg or sham injections
(n=716) in patients with minimally classic or occult CNV
secondary to AMD (Rosenfeld et al. 2006a; Fig. 2d). Data from
MARINA were further analyzed in a retrospective subgroup
analysis to determine the effectiveness of ranibizumab across
subgroups, compare the effectiveness of ranibizumab to
sham injection within subgroups, and evaluate the
relationship between selected baseline characteristics and VA
outcomes (Boyer et al. 2007).
• ANCHOR: the second pivotal phase III, multicenter,
randomized, double-masked 24-month clinical trial, which
compared ranibizumab with the active control verteporfin PDT.
ANCHOR patients were required to have predominantly classic
subfoveal AMD (n=423) and received monthly injections of
ranibizumab 0.3 or 0.5 mg combined with sham PDT or monthly
sham injections plus active verteporfin plus PDT therapy every
3 months as necessary (Brown et al. 2006; Fig. 2e).
• PIER: a phase IIIb, randomized, double-masked, sham-
controlled study that compared ranibizumab 0.3 or 0.5 mg
with sham injections in patients with primary or recurrent
subfoveal CNV with or without a classic CNV component
(n=184). The dosing regimen was three initial monthly doses
followed by mandated quarterly dosing (Kaiser et al. 2006c;
Anon. 2007a; Fig. 2f). A subgroup analysis was also
performed to provide further insights into treatment strategies
and patient monitoring (Brown et al. 2007a).
• PROTECT: there is limited evidence available in abstract form
at the time of writing from this open-label phase II study
performed in Europe. The safety and efficacy of same-day
administration of PDT with verteporfin and concomitant
intravitreal injection of ranibizumab 0.5 mg is being evaluated
in patients with predominantly classic or occult subfoveal
CNV secondary to AMD (n=32) (Schmidt-Erfurth et al. 2006;
Wolf et al. 2006).
Select ongoing and planned phase IV studies with ranibizumab
for the treatment of neovascular AMD are presented in Table 3.
Visual acuity
The effect of ranibizumab treatment on VA is summarized in
Table 4. In two of the phase II trials (FVF2128g and PrONTO) and
in the phase III trial PIER, change in VA was primarily measured as
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Study title Study description Outcome measures
Lucentis Utilizing Visudyne (LUV
Trial) Combination Therapy in
the Treatment of Age-Related
Macular Degeneration
A phase IV trial comparing the use of
combination therapy with ITV ranibizumab
and verteporfin PDT to ITV ranibizumab
alone in patients with exudative AMD
Primary outcome measure
• Best-corrected ETDRS visual acuity at 3- and 12-month time points (gain or loss
of >15 letters at 12 months)
Secondary outcome measures
• Number of ITV injections with ranibizumab needed by patients at 12 months
• OCT 3 macular thickness improvement (at baseline and 1, 2, 3, 6, and 12 months)
• Choroidal perfusion as assessed by ICG angiography at 1, 2, 3, 6, and 12 months
• Safety of combination therapy with verteporfin PDT and ITV ranibizumab
Reduced Fluence PDT With
Visudyne in Combination With
Lucentis for Age-Related
Macular Degeneration
Pilot study to evaluate the safety and
efficacy of 50% reduced fluence PDT
combination therapy with ranibizumab
Primary outcome measure
• Mean change in BCVA of ETDRS letters from baseline at 12 months
Secondary outcome measures
• Time to first re-treatment after loading doses, average number of re-treatments
over 12 months, central macular thickness on OCT, the number of recurrent
CNV, and the number of patients with persistent CNV after the mandatory
loading doses
Study Evaluating Genotypes
Using Lucentis (SEAGUL)
To investigate whether the efficacy of
ranibizumab treatment for exudative AMD
is associated with VEGF and HTRA1 DNA
polymorphisms
Primary outcome measure
• Determination of VEGF and HTRA1 genotypes associated with improvement in
visual acuity (time frame: 4 months)
Secondary outcome measures
• Determination of VEGF and HTRA1 genotypes associated with change or no
change in visual acuity (time frame: 12 months)
AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; ETDRS, Early Treatment Diabetic Retinopathy Study;
ICG, impedance cardiography; ITV, intravitreal; OCT, optical coherence tomography; PDT, verteporfin photodynamic therapy; VEGF, vascular endothelial growth factor-A.
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the mean number of letters gained or lost from baseline in
response to ranibizumab treatment compared with control. In all
other ranibizumab clinical trials, VA was primarily assessed as the
proportion of ranibizumab-treated versus control patients who
lost <15 letters from baseline.
FVF2128g
In this phase II trial comparing ranibizumab intravitreal injection to
UC, VA was assessed at all study visits. At month 3 (after
four monthly injections) VA increased 9.4ﾱ13.3 and 9.1
ﾱ17.2 letters for the ranibizumab 0.3 and 0.5 mg dose groups,
respectively. VA in the UC group decreased by a mean of 5.1
ﾱ9.6 letters during the same period. The VA benefit of
ranibizumab seen at 3 months persisted through 6 months, when
the mean change from baseline VA increased to 11.6ﾱ14.0 letters
for 0.3 mg ranibizumab and 11.8ﾱ14.1 letters for 0.5 mg
ranibizumab. At 6 months, VA of patients in the UC group
declined by a mean of 5.3ﾱ8.7 letters (Heier et al. 2006a).
PrONTO
In the PrONTO study, at month 3 (1 month after the last scheduled
monthly injection), mean VA improved by 10 letters (P<0.001). By
month 7, mean VA increased by 9 letters compared with baseline
(5 months after the last scheduled injection; P<0.001) (Rosenfeld
et al. 2006b). At month 12, mean VA remained stable at a
9.3-letter improvement from baseline (Fung et al. 2007b). An
analysis of the characteristics of patients who lost vision at year 1
of this study is available in abstract form (Fung et al. 2007a). It
appears that VA loss was associated not with a failure to initially
respond to ranibizumab therapy, but rather with anatomic
changes within the macula (Fung et al. 2007a).
FOCUS
At 12 months, 90.5% of the ranibizumab plus PDT group versus
67.9% of patients in the PDT-only group lost <15 letters (Heier
et al. 2006b). At 24 months, 87.5% of ranibizumab-treated
patients lost <15 letters, compared with 75% of patients in the
PDT-only group (P=0.04). Also at 24 months, 24.8% of
ranibizumab-treated patients gained ≥15 letters of VA versus
7.1% in the control group (P=0.006) (Lanzetta 2007). Mean VA
improved in the ranibizumab-treated group by 4.6 letters over
baseline, compared with a loss of 7.8 letters in the control group
by month 24 (P<0.0001) (Lanzetta 2007). The VA benefit
described above was apparent as early as day 7 and was
maintained throughout the study (Lanzetta 2007). In addition,
30.5% of ranibizumab-treated patients had a VA of 20/200 or
worse at month 24, compared with 50% of the PDT group
(P=0.006) (Lanzetta 2007).
MARINA
More than 90% of patients in MARINA who were treated with
ranibizumab lost <15 letters at 12 months: 94.5% of patients
treated with 0.3 mg and 94.6% of patients treated with 0.5 mg. By
comparison, 62.2% of patients in the sham group lost
<15 letters (P<0.0001) (Rosenfeld et al. 2006a). VA was improved
by ≥15 letters for a significantly (P<0.0001) greater number of
ranibizumab-treated patients (24.8% for 0.3 mg and 33.8% for
0.5 mg) versus sham-treated patients (5.0%). Mean increases in
VA from baseline were 6.5 letters for the ranibizumab 0.3 mg
group and 7.2 letters for the ranibizumab 0.5 mg group, whereas
sham-injected patients had a mean decrease of 10.4 letters. This
benefit in VA in ranibizumab-treated patients was maintained
through 24 months (Rosenfeld et al. 2006a).
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Study name Study
phase
Treatment and dose Proportion of
patients losing
<15 letters
P value Change in visual
acuity (ETDRS
letters lost
or gained)
P value Reference
FVF2128g l/ll Ranibizumab 0.3 mg
Ranibizumab 0.5 mg
Usual care
N/A +9.4ﾱ13.3
+9.1ﾱ17.2
–5.1ﾱ9.6
0.0048
0.0024
Heier et al. 2006a
FOCUS l/ll Ranibizumab 0.5 mg + PDTa
PDTa alone
90.5%
67.9%
<0.001 +4.9
–8.2
<0.001 Heier et al. 2006b
PrONTO ll
open-label
Ranibizumab 0.5 mg N/A +9.3 <0.001 Fung et al. 2007b
MARINA lll Ranibizumab 0.3 mg
Ranibizumab 0.5 mg
Sham injections
94.5%
94.6%
62.2%
<0.001
<0.001
+6.5
+7.2
–10.4
<0.001
<0.001
Rosenfeld et al. 2006
ANCHOR lll Ranibizumab 0.3 mg
Ranibizumab 0.5 mg
PDT
94.3%
96.4%
64.3%
<0.001
<0.001
+8.5
+11.3
–9.5
<0.001
<0.001
Brown et al. 2006
aPDT was permitted if fluorescein angiography revealed persistent or recurrent leakage from choroidal neovascularization lesions as determined by the investigator at any of six evaluation visits
scheduled for months 3, 6, 9, 12, 18, and 21.
AMD, age-related macular degeneration; ETDRS, Early Treatment Diabetic Retinopathy Study; PDT, verteporfin photodynamic therapy.
Table 4 | Efficacy of ranibizumab on visual acuity in the treatment of neovascular AMDANCHOR
After 12 months of treatment in ANCHOR, 94.3% of patients
receiving ranibizumab 0.3 mg and 96.4% of those receiving
0.5 mg lost <15 letters, compared with 64.3% of PDT-treated
patients (P<0.0001) (Brown et al. 2006). As in MARINA, VA
improved by ≥15 letters in significantly more ranibizumab-treated
patients (35.7% for 0.3 mg and 40.3% for 0.5 mg) than PDT-
treated patients (5.6%; P<0.0001). At 12 months, mean change in
VA increased by 8.5 letters in the ranibizumab 0.3 mg group and
by 11.3 letters in the 0.5 mg group, but decreased by 9.5 letters
in the sham group (P<0.0001). An analysis of the time course of
VA changes in the ANCHOR trial revealed that some patients who
lost VA after 3 months of treatment with ranibizumab did have
letter gains, sometimes ≥15 letters, by month 12 (Heier et al.
2007). This indicates that even patients who did not show an early
improvement in VA may still gain VA later in the course of monthly
ranibizumab treatment (Heier et al. 2007).
PIER
The PIER trial resulted in an increase in VA following three
monthly injections, at which time ranibizumab-treated patients
had a mean gain of 4.7 letters (Anon. 2007a). However, the
3-month gains were not maintained with quarterly drug
administration, and at month 12 mean VA returned to baseline
levels (mean loss of 0.2 letters) (Anon. 2007a). Over the same
period, sham-treated patients in PIER lost an average of
16.3 letters of VA. Therefore, despite the lack of overall VA gains
in ranibizumab-treated patients, the difference in VA between
ranibizumab- and sham-treated groups at month 12 was
statistically significant (P<0.01; Genentech, Inc. unpublished
data). Furthermore, the proportion of patients who lost
<15 letters at month 12 was significantly greater in the
ranibizumab group than in the control group (P<0.01; Genentech,
Inc. unpublished data). There was no statistically significant
difference in the proportion of patients who gained
≥15 letters at month 12 between the ranibizumab and sham
groups (P=0.71; Genentech, Inc. unpublished data).
PROTECT
In the PROTECT trial, verteporfin PDT and intravitreal
ranibizumab 0.5 mg were administered on the same day. The
endpoints of the trial included the incidence of severe vision loss
(≥30 letters) and the effect of treatment on BCVA (Schmidt-
Erfurth et al. 2006). No incidences of severe vision loss were
observed, and the mean change in BCVA was +4.5 letters and
+3.7 letters at 1 month and 3 months, respectively (Schmidt-
Erfurth et al. 2006).
Subgroup analyses
In a retrospective subgroup analysis of MARINA, patients were
divided based on baseline VA, age, and CNV lesion area. Within
these subgroups, <15-letter loss from baseline, ≥15-letter gain
from baseline, and mean change in VA from baseline were
determined (Boyer et al. 2007). Ranibizumab-treated patients
exhibited a statistically significant improvement compared with
sham-treated patients in all subgroups for all outcome measures.
Sham-treated patients with higher baseline VA experienced a
greater decline in VA over time than did sham-treated patients
with lower baseline VA, suggesting a “floor effect” for patients
with low baseline VA. For ranibizumab-treated patients, a higher
baseline VA was reflected in a smaller mean improvement from
baseline over time, suggesting a “ceiling effect” in those patients
with a higher baseline VA. There was no significant correlation
between increasing age, larger CNV lesion at baseline, or higher
baseline VA and loss of <15 letters, gain of ≥15 letters, or mean
change in VA in either ranibizumab- or sham-treated patients.
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Study name Treatment and dose Mean change in area of
CNV leakage (disc areas)
from baseline
P value Mean change in CNV area
from baseline (disc areas)
P value Reference
FVF2128g Ranibizumab 0.3 mg
Ranibizumab 0.5 mg
Usual care
–2.39ﾱ2.48
–1.57ﾱ2.53
0.03ﾱ1.72
0.0028
0.0699
–0.14ﾱ1.48
–0.16ﾱ2.26
0.20ﾱ1.29
0.6230
0.3557
Heier et al. 2006a
FOCUS Ranibizumab 0.5 mg + PDTa
PDTa alone
–2.3ﾱ2.4
–0.6ﾱ2.8
<0.001 –0.1ﾱ1.5
1.3ﾱ2.2
<0.001 Heier et al. 2006b
MARINA Ranibizumab 0.5 mg vs
sham injection
3-disc area mean decrease
at month 24
<0.01 2.6-disc area difference
at month 24
<0.01 Rosenfeld et al. 2006
ANCHOR Ranibizumab 0.3 mg
Ranibizumab 0.5 mg
PDT
–1.80ﾱ1.72
–2.05ﾱ1.98
0.32ﾱ3.09
<0.001
<0.001
0.20ﾱ0.97
0.22ﾱ1.25
1.63ﾱ2.37
<0.001
<0.001
Brown et al. 2006
aPDT was permitted if fluorescein angiography revealed persistent or recurrent leakage from CNV lesions as determined by the investigator at any of six evaluation visits scheduled for
months 3, 6, 9, 12, 18, and 21.
AMD, age-related macular degeneration; CNV, choroidal neovascularization; PDT, verteporfin photodynamic therapy.
Table 5 | Efficacy of ranibizumab on anatomic outcomes in the treatment of neovascular AMD, reported as changes from
baseline (SD)287
In a PIER subgroup analysis, the effect of ranibizumab was
consistent across age, sex, baseline VA, lesion size, CNV lesion
type, and laser photocoagulation history (Brown et al. 2007a).
However, the subgroup analysis revealed that patients with retinal
thickness <200 ﾵm following three monthly injections as determined
by OCT maintained their initial VA improvements through 12 months,
although they were not more likely to gain ≥15 letters than controls
(Brown et al. 2007a). Those patients who had dry lesions after the
first 3 months of treatment as determined by FA also maintained
initial improvements in VA but were more likely than controls to gain
≥15 letters (Brown et al. 2007a). Thus, patients who had a retinal
thickness ≥200 ﾵm or who had wet lesions after the first 3 months
of treatment may have benefited more from continued monthly
dosing (Brown et al. 2007a). The differences in responses of these
patient subpopulations may explain why no gain in VA was observed
at 12 months in the PIER trial.
Anatomic outcomes
Table 5 summarizes changes in mean area of CNV leakage and
CNV area in response to intravitreal ranibizumab injection. Central
retinal thickness was also assessed in some trials.
FVF2128g/FOCUS
In the phase II trials in which anatomic outcomes were reported,
ranibizumab treatment resulted in decreases in total area of CNV
and total area of leakage. In FVF2128g, the total area of CNV, total
area of leakage, and mean total lesion area decreased with
ranibizumab compared with UC (Heier et al. 2006a). In FOCUS,
the total area of the CNV lesion, the total area of CNV, leakage
from CNV, and the area of serous sensory retinal detachment
(SSRD)/subretinal fluid were all significantly decreased in patients
treated with ranibizumab plus PDT compared with those treated
with PDT alone (Heier et al. 2006b).
PrONTO
In PrONTO, final central retinal thickness as measured by OCT was
compared with baseline values (Fung et al. 2007b). At the end of
12 months of a variable ranibizumab dosing regimen, the mean
and median central retinal thickness measurements decreased by
177.8 ﾵm (P<0.001) and 185.5 ﾵm (P<0.001), respectively. The
change in retinal thickness as measured by OCT correlated with
improvements in VA; a significant correlation was found with the
Pearson analysis (r=0.38, P=0.016), although the Spearman
analysis was found to be borderline significant (r=0.31, P=0.051).
MARINA
In MARINA, mean change from baseline in growth and leakage of
CNV was significantly decreased in ranibizumab-treated patients
versus sham-treated patients at both 12 and 24 months (P<0.001)
(Rosenfeld et al. 2006a). A retrospective analysis of data from
patients in the MARINA trial also suggests that statistically
significant benefits of ranibizumab over sham were observed for
mean change from baseline in CNV area, total CNV area, and CNV
leakage (Kaiser et al. 2007).
The angiographic results of the MARINA trial and OCT
measurements of a subset of MARINA patients (those in which
the study site’s ophthalmic photographer was certified by the
University of Wisconsin Fundus Photography Reading Center,
thus reducing potential for variation by site) have been analyzed
(Kaiser et al. 2007). The exploratory FA endpoint for this analysis
included mean change from baseline in the area of SSRD at
12 and 24 months, and the exploratory endpoint for OCT was the
mean change from baseline over time in center point thickness.
Mean change in SSRD at 12 and 24 months was significantly
decreased in ranibizumab-treated patients compared with the
sham group (P<0.0001). OCT measurements from a subset of
patients (n=31 ranibizumab-treated patients pooled; n=15 sham-
treated patients) at month 12 demonstrated that the mean change
from baseline center point thickness in the sham group was
approximately zero. By contrast, in the pooled ranibizumab
groups, there was an average 84 ﾵm decrease by day 7 (P=0.010
versus sham) with a continued decrease to
123 ﾵm by month 12 (P=0.021 versus sham). The VA results in the
patients analyzed in this subset were consistent with the entire
cohort (Kaiser et al. 2007).
ANCHOR
At 12 months in the ANCHOR trial, ranibizumab-treated patients
showed significant improvements in anatomic outcomes
compared with verteporfin PDT-treated patients (Brown et al.
2006). The area occupied by classic CNV and area of leakage
from CNV decreased in both ranibizumab-treated groups and
increased in the verteporfin PDT group (P<0.001 for each
comparison). The mean area occupied by CNV (classic and
occult, if present) and mean lesion area increased in the
verteporfin PDT group, while ranibizumab-treated patients
had only small increases in these measures (P<0.001 for
each comparison).
PIER
In PIER, leakage from CNV decreased in ranibizumab-treated
patients and increased in sham-treated patients at month 12
compared with baseline (Genentech, Inc. unpublished data). The
differences in area of leakage from CNV compared with sham-
treated patients were statistically significant (P<0.01; Genentech,
Inc. unpublished data).
PROTECT
Similar results were seen in the PROTECT study. Same-day
ranibizumab and verteporfin PDT treatment was associated with
reduced CNV leakage as assessed by FA. This change was
accompanied by a statistically significant decrease in retinal
thickness (Wolf et al. 2006).
Number of treatments
Ranibizumab treatment in the FOCUS, MARINA, and ANCHOR
trials was once monthly injection for 24 months, and this regimen
resulted in significant improvements in VA for ranibizumab-treated
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results from the PIER trial in which ranibizumab was given
monthly for 3 months and quarterly thereafter indicate that VA
improvements with mandated quarterly administration were not
as robust as with a monthly schedule (Kaiser et al. 2006c; Anon.
2007a). In PrONTO, the OCT-guided treatment regimen resulted in
similar VA improvements as in MARINA and ANCHOR, but with
fewer treatments (Fung et al. 2007b). Once a fluid-free macula
was achieved, the mean injection-free interval was 4.5 months
(Fung et al. 2007b). However, no trials have directly evaluated the
administration of ranibizumab on a when-required basis
compared with monthly dosing.
Quality of life
Data on patient-reported quality of life (QOL) and vision-related
function (VRF) from the MARINA and ANCHOR trials are available
in abstract form (Chang et al. 2006; Chang et al. 2007; Schwartz
et al. 2007; Suner et al. 2007). Patient-reported vision-specific
QOL was assessed using the National Eye Institute Function
Questionnaire-25 (NEI VFQ-25). In MARINA, perception of driving
function decreased less in ranibizumab-treated patients than in
sham-treated patients over 24 months (Chang et al. 2007).
Furthermore, overall self-reported vision-specific QOL improved
in ranibizumab-treated patients, while sham-treated patients
reported decreases (Chang et al. 2006). These improvements in
vision-specific QOL resulted in decreased levels of vision-related
dependency for ranibizumab compared with sham-treated
patients (Chang et al. 2006). VRF also improved at 24 months
following ranibizumab treatment compared to sham (Suner et al.
2007). Similar improvements in VRF and QOL were found through
month 12 in ANCHOR (Schwartz et al. 2007).
Safety and tolerability
The safety and tolerability of ranibizumab intravitreal injection has
been consistently demonstrated. In the FVF2128g trial, ranibizumab
was generally well tolerated (Heier et al. 2006a). In FOCUS, there
was no notable imbalance in the incidence of serious nonocular AEs
between the treatment groups (ranibizumab + PDT versus PDT
alone) (Heier et al. 2006b), although the ranibizumab plus PDT group
had more vascular system AEs (8.6 versus 5.4%; P=0.54) and fewer
other AEs (9.5 versus 14.3%; P=0.43) than the PDT group (Heier et
al. 2006b). There were no ocular or systemic AEs attributable to the
injection of ranibizumab in PrONTO (Fung et al. 2007b). In MARINA,
the three treatment groups did not differ in their rates of nonocular
AEs (Rosenfeld et al. 2006a). Serious ocular AEs were attributable
either to the injection procedure (presumed endophthalmitis) or to
ranibizumab (serious uveitis) (Rosenfeld et al. 2006a). Similar results
were observed in ANCHOR with balanced ocular and non-ocular
safety profiles for all treatment arms, although there was a trend
toward increased rates of intraocular inflammation in ranibizumab-
treated patients (10.2% in the 0.3 mg ranibizumab group, 15.0% in
the 0.5 mg ranibizumab group, and 2.8% in the PDT with verteporfin
group) (Brown et al. 2006). Through month 12 of PIER, there were no
reported serious ocular AEs potentially related to intravitreal injection
and no nonocular AEs that might be associated with anti-VEGF
therapy as a class (Genentech, Inc. unpublished data).
Ocular AEs
There were no episodes of endophthalmitis, uveitis, retinal
detachment, retinal tear, vitreous hemorrhage, lens damage,
cataract progression, or prolonged intraocular pressure (IOP)
elevation in PrONTO (Fung et al. 2007b). Ocular AEs were
reported in the other trials, as discussed below.
Intraocular inflammation
In FVF2128g, the most common AE was reversible
inflammation of 2+ to 4+ (inflammation was evaluated by
grading flare and cells from 0 to 4+), which occurred after 8%
of injections; trace or greater inflammation occurred after 58%
of injections (Heier et al. 2006a). The 2+ to 4+ inflammatory
responses were most severe on the day after injection, and
usually resolved without treatment by 14 days after injection
(Heier et al. 2006a). In FOCUS, a total of 13 episodes of serious
intraocular inflammation occurred in 12 patients (11.4%) from
the ranibizumab plus PDT group but none occurred in the PDT
group (P=0.009) (Heier et al. 2006b). This inflammation may
have been due to the lyophilized ranibizumab preparation used
in the first 12 months of this study. This hypothesis is
supported by safety data from PROTECT, where the
commercial preparation was used. Furthermore, this
inflammation was not apparent in the MARINA slit-lamp
examination of patients, who had only trace or 1+ across all
groups (Rosenfeld et al. 2006a). In ANCHOR, the rates of
intraocular inflammation were slightly higher in both
ranibizumab groups compared with the verteporfin PDT group,
and were consistent with MARINA (Brown et al. 2006). Overall,
however, most patients had no observable inflammation, and
the proportion of inflammation events graded 2+ or higher
among ranibizumab-treated patients was small (Brown et
al. 2006).
Injection-site hemorrhage and retinal tear
The rates of retinal tear and vitreous hemorrhage were low in all
ranibizumab-treated patients. In FVF2128g, one (1.9%) patient
had a retinal tear (Heier et al. 2006a). Vitreous hemorrhage
occurred in 3.9–5.7% of ranibizumab-treated patients; the
vitreous hemorrhage was severe in one patient, but it occurred in
association with central retinal vein occlusion (CRVO) and
resolved after 208 days (Heier et al. 2006a). The incidence of
vitreous hemorrhage and retinal tear was also low in MARINA
(0.4% in both ranibizumab groups for both types of event)
(Rosenfeld et al. 2006a). One event of vitreous hemorrhage was
reported in ANCHOR, in a patient treated with ranibizumab
0.3 mg, and there were no reports of retinal tear in this trial (Brown
et al. 2006).
Increases in intraocular pressure
Increases in IOP were mostly mild and transient, resolving without
treatment in FVF2128g (Heier et al. 2006a). In FOCUS, transient
increased IOP AEs were reported in 16.2% of the ranibizumab
plus PDT group versus 1.8% in the PDT-alone group (P=0.007)
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(Heier et al. 2006b). The likelihood of experiencing a transient
increase in IOP did not change significantly with repeated
injections. Despite these increases in IOP, there was no notable
increased incidence of cataract (P>0.99) (Heier et al. 2006b).
Ranibizumab had no long-term effect on IOP as assessed by
monthly preinjection measurements during the 2-year follow-up
period in MARINA (Rosenfeld et al. 2006a). IOP was increased
1 hour after ranibizumab injections, but the absence of
corresponding changes in preinjection measurements suggests
that the postinjection increases were transient. Ranibizumab was
not associated with an increased frequency of cataracts
(Rosenfeld et al. 2006a).
In ANCHOR, transient changes in IOP after injections were
common in the ranibizumab-treated patients (Brown et al. 2006).
The proportion of patients with a postinjection IOP of ≥30 mmHg
was greater in both ranibizumab groups than in the verteporfin
PDT group, but very few patients had measurements of
≥40 mmHg. The ranibizumab groups had an increased frequency
of cataract formation (10.9% in the 0.3 mg group, 12.9% in the
0.5 mg group, and 7.0% in the verteporfin group) and a small
number of patients had changes in lens status reported during the
first treatment year. With the exception of one severe cataract
formation in the verteporfin PDT group, all AEs associated with
cataracts were mild or moderate (Brown et al. 2006).
Nonocular AEs
Vascular AEs
Vascular AEs are a potential risk with anti-VEGF therapies,
although this risk is minimal with intravitreal administration. In
FOCUS, the rate of arterial thromboembolic events (ATEs) was
similar for patients treated with ranibizumab plus PDT or PDT
alone (Heier et al. 2006b). Treatment-emergent hypertension was
reported at a higher rate in ranibizumab-treated patients, although
all episodes in both treatments were described as mild, except for
two patients in the ranibizumab plus PDT group whose
hypertension was described as moderate. There were no
imbalances between treatment groups in any type of bleeding AE.
In PrONTO, no systemic thromboembolic events occurred and no
hypertension was newly diagnosed during the study (Fung et al.
2007b). After 1 year, there were mean decreases in systolic blood
pressure (8 mmHg) and diastolic blood pressure (5 mmHg).
At 24 months in MARINA, the rate of AEs did not differ
significantly among treatment groups (Rosenfeld et al. 2006a).
Furthermore, the onset of AEs and the time of study treatment
appeared to be unrelated. By 24 months, nonocular hemorrhage
had occurred in more ranibizumab-treated patients than sham-
injected patients, but none of the differences were significant
(Rosenfeld et al. 2006a). Similarly, in ANCHOR, the differences in
rates of AEs among treatment groups were not significant
(Brown et al. 2006). No apparent relationship between the onset
of those events and the time of treatment was observed. There
was also no increase in mean systolic or diastolic blood pressure
or in the rates of hypertension in the ranibizumab groups
compared with control.
Recently, a planned interim safety analysis of an ongoing phase III
study (SAILOR) indicated a higher incidence of stroke in patients
treated with ranibizumab 0.5 mg compared with those treated
with 0.3 mg (1.2 versus 0.3%, respectively; P=0.02) (Anon.
2007b). Patients with a history of prior stroke appeared to be at a
higher risk for a subsequent stroke. However, the incidence of
stroke determined in the SAILOR interim analysis was less than
the US average for strokes, which is 2.4% across all ages, and
increases with age [age-adjusted incidence 2.2% in the
45–64 age group, 6.2% in the 65–74 age group, and 12.5% in the
75-and-over age group (Pleis & Lethbridge-ￇejku 2006)]. For the
AEs of myocardial infarction or vascular death, the differences
between the doses were not statistically significant. As this was
an interim analysis, no firm conclusions can be drawn; a full
analysis will be performed after the completion of the study, at
which time more accurate determinations of stroke risk can
be established.
Development of antiranibizumab antibodies
Because ranibizumab is a humanized Fab, it is expected to be
less antigenic than full-length monoclonal antibodies, chimeric
antibodies, or other large foreign molecules (Heier et al. 2006a).
Systemic immunoreactivity to ranibizumab may reflect detection
of preexisting antibodies to endogenous Fab fragments rather
than specific antibodies to ranibizumab (Heier et al. 2006b). In
FVF2128g, serum antibody assays indicated that no patient
developed new antiranibizumab antibodies (Heier et al. 2006a).
Systemic immunoreactivity to ranibizumab was present in some
patients at baseline in FOCUS (Heier et al. 2006b), MARINA
(Rosenfeld et al. 2006a), and ANCHOR (Brown et al. 2006). In
FOCUS, the percentage of ranibizumab-treated patients testing
positive for immunoreactivity did not exceed the percentage in the
PDT-alone group, and review of the VA data and AEs revealed no
clinically relevant effects in patients with positive
immunoreactivity (Heier et al. 2006b). In MARINA,
immunoreactivity rates increased similarly in all treatment groups
during the first year. Although more ranibizumab-treated than
sham-treated patients tested positive at month 24, exploratory
subgroup analyses revealed no clinically relevant differences
between patients with or without immunoreactivity to ranibizumab
(Rosenfeld et al. 2006a). Monitoring for immunoreactivity during
the first treatment year of ANCHOR revealed an increase from
baseline in the number of patients testing positive in the 0.5 mg
group but not the 0.3 mg or verteporfin groups at 12 months.
Proportionately more ranibizumab-treated patients who were
immunoreactive at any point during ANCHOR had AEs associated
with intraocular inflammation, although the small number of
patients with immunoreactivity precludes drawing definitive
conclusions (Brown et al. 2006). Immunoreactivity appeared to be
unrelated to VA changes and nonocular AEs potentially related to
immunoreactivity (Brown et al. 2006). Therefore, the clinical
significance of the increased rate of systemic immunoreactivity
with ranibizumab treatment is still unclear (Rosenfeld et
al. 2006a).
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In the US, ranibizumab is covered under Medicare Part B,
although patients are responsible for a 20% copayment after
each injection (Steinbrook 2006). In many instances,
supplemental insurance, Medicaid, or support programs for the
poor or uninsured that are funded by the manufacturer or others
cover most or all of the patients’ out-of-pocket costs.
Ranibizumab treatment results in significant QOL benefits and
has been shown to provide superior value to neovascular AMD
patients (Brown et al. 2007c). For ophthalmologic interventions, in
which length of life is generally unaffected, the value gain is
equivalent to the improvement in QOL (Brown et al. 2007b,c).
Preliminary data suggest the value gain for the treatment of
occult/minimally classic CNV with ranibizumab is greater than
15% (Brown et al. 2007c). In comparison, PDT with verteporfin
treatment delivers a value gain of 8.1% for classic subfoveal CNV,
pegaptanib sodium a 5.9% increase for subfoveal CNV, and laser
photocoagulation a 4.4% increase for classic subfoveal CNV
(Brown et al. 2007b,c).
Brown and colleagues posit that the value of a treatment has
nothing to do with cost, although cost can be a legitimate
secondary consideration (Brown & Brown 2007). Although the
cost of off-label bevacizumab is significantly lower than that of
ranibizumab (Steinbrook 2006, Raftery et al. 2007), ranibizumab
was specifically designed, tested, and approved for neovascular
AMD. Its efficacy and safety have been demonstrated in several
large, rigorous clinical trials, as discussed above. In
retrospective and small prospective studies, off-label
bevacizumab appears to have similar efficacy to ranibizumab,
but a head-to-head trial of efficacy and safety has not yet been
conducted, and rigorous clinical trial data are lacking in general
for off-label bevacizumab in neovascular AMD (Raftery et al.
2007). Therefore, given the wealth of level 1 clinical data and
documented QOL value gain of ranibizumab, it would seem that
this treatment is currently the best option for neovascular
AMD patients.
Patient group/population
Ranibizumab (Lucentis) is indicated for the treatment of patients
with neovascular AMD (Anon. 2007a). This broad indication
allows for treatment of all types of neovascular AMD-related
lesions to be treated with ranibizumab. The two pivotal phase III
trials and the additional supportive phase III trials for
ranibizumab included patients with all three angiographic
subtypes: predominantly classic, minimally classic, and occult.
As with all clinical trials, there is some selection bias introduced
by the inclusion/exclusion criteria. The exclusion criteria for
these two trials restricted enrollment of patients with prior
treatment of the study eye with verteporfin, external-beam
radiation therapy, transpupillary thermotherapy (TTT),
antiangiogenic drugs, or those with previous intravitreal drug
delivery, vitrectomy, or submacular surgery. Other exclusion
criteria were based on particular lesion characteristics including
those patients with subretinal hemorrhage involving the center
of the fovea, lesions with hemorrhage that was ≥50% of the total
lesion area or ≥1 disc area in size, subfoveal fibrosis or atrophy,
or CNV in either eye due to other causes, such as ocular
histoplasmosis, trauma, or pathologic myopia.
Analysis of subgroups of patients from MARINA indicated that the
most important predictors of VA outcomes may be baseline VA
score, CNV lesion size, and age (in that order), although
ranibizumab treatment for 24 months was consistently superior to
sham treatment in all subgroups examined (Boyer et al. 2007). A
greater net benefit in AMD patients treated with ranibizumab
compared with sham was seen in patients with higher baseline VA
(Boyer et al. 2007), but overall, the subgroup analyses suggest
that all patients with neovascular AMD can benefit from
ranibizumab treatment.
Ranibizumab is contraindicated in patients with ocular or
periocular infections and in patients with known hypersensitivity
to ranibizumab or any of the excipients in ranibizumab
(Anon. 2007a).
Dosage, administration, and formulations
Ranibizumab is an ophthalmic-grade solution for intravitreal
injection only (Anon. 2007a). The recommended schedule and
dose of ranibizumab for the treatment of neovascular AMD is via
intravitreal injection once a month at a dose of 0.5 mg (Anon.
2007a). The injection frequency can be reduced to one injection
every 3 months after the first four injections if monthly injections
are not feasible; however, this interval is less effective and is likely
to lead to an approximate 5-letter loss of VA benefit over the
following 9 months (Anon. 2007a). Ranibizumab should be
administered under controlled aseptic conditions with adequate
anesthesia and a broad-spectrum microbicide given prior to the
injection (Anon. 2007a). Patients should be monitored for elevation
in IOP and endophthalmitis following the injection (Anon. 2007a).
The use of OCT to guide the treatment regimen in the PrONTO
trial resulted in similar VA increases as seen in MARINA and
ANCHOR but with fewer treatments (Fung et al. 2007b). The
outcomes suggest that OCT can be useful for guiding re-
treatment with intravitreal ranibizumab, and the use of an OCT-
guided dosing regimen may decrease the injection burden
without necessarily sacrificing improvements in VA (Fung et al.
2007b). A decrease in the number of injections would also reduce
the potential risk of injection-related complications, and an
increase in the injection-free interval could reduce the burden of
frequent follow-up evaluations (Fung et al. 2007b). No direct
comparison of the efficacy of as-required injection versus monthly
injection of ranibizumab has been made to date, and treatment
recommendations should follow the approved regimen until
additional data are available.
Place in therapy
Neovascular AMD is the leading cause of blindness in the elderly,
and owing to the increasing age of the population, the number of
persons with neovascular AMD may increase by 50% to
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2.95 million by 2020 (Friedman et al. 2004). There is no known
method of preventing the development of advanced AMD
(SanGiovanni et al. 2007) or CNV. However, it is clear that
angiogenesis and vascular permeability are driven by VEGF-A
(Kaiser 2006a; Kaiser & Do 2007). Since VEGF-A is an important
regulator of angiogenesis, it has become an important target for
the treatment of ocular diseases, such as neovascular AMD, in
which angiogenesis plays a role (Kaiser 2006a).
Several anti-VEGF-A therapies for AMD are available and others
are currently in development (Kaiser 2006a). Current treatment
guidelines discuss options for anti-VEGF-A therapy, including
pegaptanib, ranibizumab, and off-label bevacizumab. Although
bevacizumab is not approved by the FDA for use in neovascular
AMD, the AAO Retina Panel does present the drug as an option
as a therapy for neovascular AMD, with the caveat that the
treating physician should provide appropriate informed consent
with respect to the off-label status of bevacizumab (AAO 2006).
The superior efficacy of ranibizumab compared with verteporfin PDT
has been demonstrated in the clinical trials. In the ANCHOR trial,
ranibizumab was superior to verteporfin for treatment of
predominantly classic neovascular AMD (Brown et al. 2006).
Patients treated with ranibizumab showed statistically significant
improvements in VA and a greater proportion lost <15 letters of VA
compared with patients treated with PDT. Furthermore, ranibizumab
resulted in significant improvements in anatomic characteristics
such as the area occupied by CNV and the area of leakage.
In the FOCUS trial, the addition of ranibizumab treatment to PDT
therapy was significantly more efficacious than PDT alone; there
was no ranibizumab-alone arm in this trial, and thus the relative
contribution of PDT to overall efficacy cannot be determined. It is
clear that the addition of monthly ranibizumab to verteporfin PDT
greatly reduced the need for additional verteporfin PDT
treatments (Heier et al. 2006b). An ongoing clinical development
program (SUMMIT) is designed to further explore the combination
of PDT therapy plus ranibizumab and to provide insight into the
efficacy, safety, treatment practice, and health economics of this
combination therapy.
As demonstrated in the PrONTO trial, the use of OCT to guide the
treatment regimen of ranibizumab resulted in similar VA
improvements as in MARINA and ANCHOR but with fewer
treatments, suggesting that the use of OCT to guide re-treatment
with ranibizumab may decrease the injection burden (Fung et al.
2007b). A direct head-to-head trial will be necessary to
unequivocally conclude that a variable dosing regimen using OCT is
noninferior to a fixed monthly dosing regimen (Fung et al. 2007b).
The approval of ranibizumab for neovascular AMD has changed
the definition of VA “maintenance”. Prior to the demonstration
that ranibizumab treatment could improve VA in patients with
neovascular AMD, the loss of <15 letters of VA was considered
maintenance. Ranibizumab has raised the treatment standard in
that it has the potential to increase VA in many patients. Similarly,
physician and patient expectations about anticipated outcomes
following treatment for neovascular AMD have changed as well.
Ranibizumab also provides value when compared with many other
neovascular AMD treatments. The value gain for the treatment of
occult/minimally classic CNV with ranibizumab is greater than 15%,
compared with 4.4% for laser photocoagulation, 5.9% for
pegaptanib sodium, and 8.1% for verteporfin PDT for subfoveal
CNV (Brown et al. 2007c). Brown and colleagues also note that the
value conferred by an intervention, rather than the associated cost
effectiveness, should be the most important factor when deciding
how to treat a patient (Brown et al. 2007b, Brown & Brown 2007).
Although ranibizumab has a significantly higher price than off-label
bevacizumab (Raftery et al. 2007), the efficacy and safety of off-label
bevacizumab have not been determined in randomized clinical trials,
and off-label bevacizumab is not approved by the FDA for the
treatment of neovascular AMD.
Clinical evidence supports the use of ranibizumab injection as a first-
line therapy in neovascular AMD patients. Current treatment
guidelines from the AAO Retinal Panel recommend ranibizumab for
patients with subfoveal CNV (AAO 2006). The trial data indicate that
all neovascular AMD patient groups are likely to benefit from
ranibizumab therapy; therefore, there appears to be evidence to
support the view that the current treatment guidelines should be
updated to recommend ranibizumab as a preferred first-line therapy
for all neovascular AMD patients.
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